相似文献
1
Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
In Vivo. 2020 Sep-Oct;34(5):2653-2657. doi: 10.21873/invivo.12084.
2
Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Medicina (Kaunas). 2021 Oct 23;57(11):1151. doi: 10.3390/medicina57111151.
3
Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma.
Int J Clin Oncol. 2021 Jul;26(7):1188-1195. doi: 10.1007/s10147-021-01907-x. Epub 2021 Apr 5.
4
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Cancer Med. 2021 Jun;10(12):3952-3963. doi: 10.1002/cam4.3953. Epub 2021 May 25.
5
Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors.
Clin Transl Oncol. 2017 Jun;19(6):769-776. doi: 10.1007/s12094-016-1604-z. Epub 2017 Jan 24.
6
Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study.
PLoS One. 2022 Jul 28;17(7):e0271907. doi: 10.1371/journal.pone.0271907. eCollection 2022.
7
Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial.
Cancer Control. 2021 Jan-Dec;28:1073274821997444. doi: 10.1177/1073274821997444.
8
A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.
ESMO Open. 2024 Jun;9(6):103476. doi: 10.1016/j.esmoop.2024.103476. Epub 2024 Jun 3.
9
Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Auris Nasus Larynx. 2020 Feb;47(1):116-122. doi: 10.1016/j.anl.2019.05.001. Epub 2019 May 23.
10
Efficacy of Cetuximab Combined with Paclitaxel in Patients with Recurrent Salivary Gland Carcinoma: A Retrospective Observational Study.
ORL J Otorhinolaryngol Relat Spec. 2024;86(1):41-49. doi: 10.1159/000534516. Epub 2023 Dec 13.
引用本文的文献
1
Efficacy of Paclitaxel and Cetuximab in Recurrent/Metastatic Oral Cancer Cases Following Superselective Intraarterial Chemoradiotherapy: A Retrospective Cohort Study.
Cancer Diagn Progn. 2024 Nov 3;4(6):769-774. doi: 10.21873/cdp.10394. eCollection 2024 Nov-Dec.
2
Chemotherapy following immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: clinical effectiveness and influence of inflammatory and nutritional factors.
Discov Oncol. 2023 Aug 29;14(1):158. doi: 10.1007/s12672-023-00774-4.
3
Induction Chemotherapy With 5-Fluorouracil, Cisplatin, and Cetuximab in Advanced Head and Neck Squamous Cell Carcinoma.
In Vivo. 2023 May-Jun;37(3):1275-1280. doi: 10.21873/invivo.13205.
4
Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review.
Cancer Rep (Hoboken). 2023 May;6(5):e1802. doi: 10.1002/cnr2.1802. Epub 2023 Apr 12.
5
Real-world Data of Paclitaxel and Cetuximab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
Cancer Diagn Progn. 2023 Mar 3;3(2):264-271. doi: 10.21873/cdp.10211. eCollection 2023 Mar-Apr.
6
Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Medicina (Kaunas). 2021 Oct 23;57(11):1151. doi: 10.3390/medicina57111151.
本文引用的文献
1
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1.
2
The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions.
Front Oncol. 2019 Aug 21;9:668. doi: 10.3389/fonc.2019.00668. eCollection 2019.
3
Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK.
Front Oncol. 2018 Dec 13;8:616. doi: 10.3389/fonc.2018.00616. eCollection 2018.
4
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
5
A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma.
Oral Oncol. 2017 Oct;73:21-26. doi: 10.1016/j.oraloncology.2017.07.022. Epub 2017 Aug 5.
6
Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Front Oncol. 2017 May 9;7:72. doi: 10.3389/fonc.2017.00072. eCollection 2017.
7
A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers.
South Asian J Cancer. 2017 Jan-Mar;6(1):11-14. doi: 10.4103/2278-330X.202558.
8
Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors.
Clin Transl Oncol. 2017 Jun;19(6):769-776. doi: 10.1007/s12094-016-1604-z. Epub 2017 Jan 24.
9
Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma.
Laryngoscope. 2017 Jul;127(7):1583-1588. doi: 10.1002/lary.26422. Epub 2016 Dec 1.
10
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8.
Zotero 插件